Zhejiang CONBA Pharmaceutical Co., Ltd. Class A 600572
SSE · China · Health Technology
CNY 4.31+0.07 (+1.65%)
Market closed· · CNY · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · CNY · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Agreement Grants Conba Rights for the Development and Commercialization of Cebranopadol for Pain Across Mainland China, Hong Kong, Macao and Taiwan, representing an important step in expanding the global potential of cebranopadol Under the Terms of the Agreement, Conba Will Pay an Upfront Payment of $17.5 Million (USD), Along with Development and Commercial Milestone Payments Totaling More Than $100 Million (USD), and Tiered Royalties on Net Sales Starting in the Double Digits Adneuris Anticipat
Amidst a backdrop of rising inflation concerns and fluctuating consumer sentiment, global markets have shown resilience with major U.S. stock indexes reaching new highs. In this context, investors often seek opportunities in smaller or newer companies that can offer unique value propositions. Penny stocks, despite their somewhat outdated moniker, continue to attract attention for their potential to combine affordability with growth prospects when backed by robust financials.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.